David R. Patton - Concepedia

Author

David R. Patton

National Cancer Institute ORCID

Also Known As

D Patton, D. Patton, D.R. Patton, David Patton, David R Patton, David R. Patton, Keith T. Flaherty, Patton, David R.

220

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Massachusetts General Hospital Frederick National Laboratory for Cancer Research

About

David R. Patton is an author at National Cancer Institute specializing in medicine, oncology, and molecular oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	597
2	Health Sciences	6	6	167
3	Public Health	2	2	70
4	Engineering	1	1	36
5	Biochemistry	1	1	36

David R. Patton

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Early and Longitudinal Evaluations of Treated Infants and Children and Untreated Historical Patients with Congenital Toxoplasmosis: The Chicago Collaborative Treatment Trial James McAuley, K. M. Boyer, Dushyant V. Patel, Clinical Infectious Diseases	1994	401
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Journal of Clinical Oncology	2020	281
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF<sup>V600E</sup></i> Mutations: Results of the NCI-MATCH Trial Subprotocol H April K.S. Salama, Shuli Li, Erin Macrae, Journal of Clinical Oncology	2020	277
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design Keith T. Flaherty, Robert J. Gray, Alice P. Chen, JNCI Journal of the National Cancer Institute	2020	221
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W Young Kwang Chae, Fangxin Hong, Christos Vaklavas, Journal of Clinical Oncology	2020	175
Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study Nilofer S. Azad, Robert J. Gray, Michael J. Overman, Journal of Clinical Oncology	2019	163
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q Komal Jhaveri, X.V. Wang, Vicky Makker, Annals of Oncology	2019	138
Nephrotic Plasma Alters Slit Diaphragm–Dependent Signaling and Translocates Nephrin, Podocin, and CD2 Associated Protein in Cultured Human Podocytes Richard J. Coward, Rebecca R. Foster, David R. Patton, Journal of the American Society of Nephrology Normal Human PlasmaImmunologyRenal InflammationCytoskeletonCellular Physiology	2005	120
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, JAMA Oncology	2020	101
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma Jane N. Winter, David J. Inwards, Stewart Spies, Journal of Clinical Oncology	2009	99

Page 1